tirzepatide kidney pain (Zepbound) showed improved function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Tirzepatide Side Effects: Common &

Obesity Doctor: 5 Signs Your GLP-1 Is Working Correctly What to Track on GLP-1 Therapy Tracking the right metrics is crucial for making the most of GLP-1 therapy

Most people see noticeable results after 36 treatments, spaced a few weeks apart

Quality grass fed & finished protein sources Cruciferous vegetables to support phase one and phase two liver detoxification

For many patients, the weekly schedule is one of the biggest advantages

What used to be a $1 or $1.5 billion market space is now a $5 or $6 billion market space and it is growing very rapidly because more and more drugs are coming out into the market, which are peptides. Saharsh Davuluri, Vice-Chairman & MD, Neuland Laboratories | Q1 FY26 Its not just about the weight loss drugs that have been commercialized, but its also about the next gens, not just from the large companies, but other companies as well